Key statistics
As of last trade Lantheus Holdings Inc (0L8:FRA) traded at 82.74, -27.61% below its 52-week high of 114.30, set on Jul 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 82.74 |
---|---|
High | 82.74 |
Low | 82.74 |
Bid | 83.08 |
Offer | 83.90 |
Previous close | 81.44 |
Average volume | 692.56 |
---|---|
Shares outstanding | 69.53m |
Free float | 67.81m |
P/E (TTM) | 14.51 |
Market cap | 6.07bn USD |
EPS (TTM) | 6.02 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:07 GMT.
More ▼
- Lantheus Announces Share Repurchase Program
- Lantheus to Present at the Jefferies London Healthcare Conference
- Lantheus Continues to Commend CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY’s Blockbuster Status for 2025
- Lantheus Reports Third Quarter 2024 Financial Results
- Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
- Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time
- Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
- Lantheus Appoints Julie Eastland as New Board Member
- Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
More ▼